Breaking News Headlines Today | Ground News

See every side of every news story

cancernetwork.com image

News from cancernetwork.com

See all of cancernetwork.com news coverage in one place. Discover how cancernetwork.com’s media bias informs their coverage and compare with thousands of other news outlets.

Ground News has come across 685 headlines reported on by cancernetwork.com during the past 3 months.

Ground News rates cancernetwork.com’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Is cancernetwork.com credible or reliable? Our Factuality score answers both of those questions. When it comes to cancernetwork.com, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.

Information about cancernetwork.com

Where is cancernetwork.com located?cancernetwork.com's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top cancernetwork.com News

Artificial Intelligence Helps Doctors Detect Breast Cancer Better

Artificial Intelligence · North Carolina

Artificial Intelligence Helps Doctors Detect Breast Cancer Better

55% Center coverage: 18 sources

Researchers found that AI improves breast cancer detection accuracy for radiologists.See the Story

U.S. FDA Grants Orphan Drug Designation to Adcentrx Therapeutics' ADRX-0405 STEAP1 ADC for Gastric Cancer

Cancer · United States

U.S. FDA Grants Orphan Drug Designation to Adcentrx Therapeutics' ADRX-0405 STEAP1 ADC for Gastric Cancer

94% Center coverage: 16 sources

Orphan drug designation highlights the potential for ADRX-0405 to address the high unmet need in gastric cancer See the Story

Excess Weight Linked to Breast Cancer Risk in Postmenopausal Women with Cardiovascular Disease

Excess Weight Linked to Breast Cancer Risk in Postmenopausal Women with Cardiovascular Disease

80% Center coverage: 5 sources

New research reveals that excess weight is linked to an especially high risk of developing breast cancer in postmenopausal women with cardiovascular disease.See the Story

Sirtex Medical's SIR-Spheres® Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable Hepatocellular Carcinoma

100% Center coverage: 1 sources

/PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of interventional oncology solutions, today announced that the U.S. Food and Drug...United States · United States See the Story

Future Directions and Unmet Needs in CLL/SLL Treatment

Panelist discusses how recent ASCO updates, particularly the SEQUOIA study results, highlight the long-term efficacy of zanubrutinib in high-risk patients and represent the most significant advances in CLL treatment from the meeting.See the Story

Real-World Data Show Activity With Ivosidenib in IDH1+ Cholangiocarcinoma

Data from the phase 3b ProvIDHe trial show "reassuringly good" PFS and OS outcomes with ivosidenib in a real-world cohort.Read Article

Characterizing Tumor Cell Diversity with AI

“Developments that take high-dimensional data and come up with interpretable insights…are going to play an increasing role,” says Smita Krishnaswamy, PhD.Artificial Intelligence Read Article

Enzalutamide Prolongs Survival in nmHSPC With Biochemical Recurrence

More detailed overall survival results from the phase 3 EMBARK trial for patients with nmHSPC will be shared at an upcoming medical conference.Read Article

Tislelizumab/Chemotherapy Earns EU Approval in Nasopharyngeal Carcinoma

Data from the RATIONALE-309 trial support the European Commission’s approval of frontline tislelizumab plus chemotherapy in this patient population.European Union See the Story

Tarlatamab Shows Promising Real-World Activity in Extensive-Stage SCLC

Treatment with tarlatamab demonstrated intracranial responses in a real-world cohort of patients with extensive-stage small cell lung cancer.Read Article

Optimal Dosing of Talquetamab

Panelists discuss how to operationalize talquetamab dosing in community settings by addressing the main challenges of infection risk and skin toxicity through patient education, proactive monitoring protocols, and careful patient selection, with early community experience showing manageable toxicity rates and the importance of setting proper expectations about skin and nail changes as markers of drug activity rather than concerning adverse effec…United States · United States Read Article

Breaking News Topics Related to cancernetwork.com